A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 2b Study to Evaluate the Efficacy and Safety of Multiple Doses of BLU-5937 in Adult Participants With Refractory Chronic Cough
A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 2b Study to Evaluate the Efficacy and Safety of Multiple Doses of BLU-5937 in Adult Participants With Refractory Chronic Cough
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 2b adaptive dose-finding study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
The primary objective of this study is to determine the therapeutic dose of BLU-5937 in patients with refractory chronic cough by assessing the change from baseline to week 4 in the 24-hour cough frequency with BLU-5937 relative to placebo.
Inclusion Criteria:
Exclusion Criteria:
Los Angeles, California 90048, United States
San Jose, California 95117, United States
Toronto, Quebec M5T 3A9, Canada
Strakonice, South Bohemia 386 01, Czechia
Neu-Isenburg, Hesse 63263, Germany
Tatabánya, Nógrád megye 2800, Hungary
Bydgoszcz, Kuyavian-Pomeranian Voivodeship 31-826, Poland
Tarnów, Lesser Poland Voivodeship 33-100, Poland
Lublin, Lublin Voivodeship 20-552, Poland
Kraków, Łódź Voivodeship 31-572, Poland
Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship 27-400, Poland